Loading...
XTAI1783
Market cap127mUSD
Dec 25, Last price  
46.90TWD
1D
-0.21%
1Q
10.35%
Jan 2017
128.56%
IPO
127.56%
Name

Maxigen Biotech Inc

Chart & Performance

D1W1MN
XTAI:1783 chart
P/E
25.22
P/S
6.72
EPS
1.86
Div Yield, %
1.01%
Shrs. gr., 5y
0.95%
Rev. gr., 5y
7.78%
Revenues
622m
+2.93%
180,604,000172,440,000178,876,000221,997,000232,947,000245,686,000261,469,000336,388,000427,561,000427,680,000452,199,000457,691,000511,976,000604,431,000622,115,000
Net income
166m
+18.95%
12,627,000-16,000,000-36,073,0002,764,0002,584,000-19,041,000-62,959,000-12,247,00015,787,00057,055,00060,111,00063,311,00087,667,000139,404,000165,828,000
CFO
171m
-36.20%
19,271,000-16,764,000-76,640,00017,526,000-22,336,000-14,451,000-109,850,00034,718,00041,176,000170,581,00094,418,00074,394,000117,593,000268,338,000171,200,000
Dividend
Jul 23, 20240.99873 TWD/sh
Earnings
Jun 13, 2025

Profile

Maxigen Biotech Inc. engages in the development, manufacture, and marketing of biomedical and skincare products in Taiwan and internationally. The company offers Formagraft, a bone graft substitute; Formasetin, a bone void filler; and intra-articular injections under the ArtiAid, ArtiAid Plus, and ArtiBest names for use in orthopedic area. It also provides Foramic, a bone substitute granule; MaxiBone, a calcium phosphate ceramic; and GingivAid, a collagen dental grafts for use in orthopedic and dental areas. In addition, the company offers FormaAid, a collagen membrane; and E-TECH DENTISTAR II sterilizer and disinfectant for use in dental area, as well as HealiAid, a collagen wound dressing product for use in dental and wound dressing area. Further, it provides ophthalmic viscoelastic device under the ViscAid, PreviscAid, and BiVisc names; and Formaderm, a dermal filler injection for use in plastic surgery. Additionally, the company offers skincare products, including face, neck, body, limbs, and other masks; and make up remover, cleansing, exfoliating, toner, essence, men's care, sunscreen, body care, hand/foot care, and special care products. Maxigen Biotech Inc. was founded in 1998 and is based in Taoyuan City, Taiwan.
URL
https://mbi-bio.com/
IPO date
May 18, 2011
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
622,115
2.93%
604,431
18.06%
511,976
11.86%
Cost of revenue
472,066
471,099
419,005
Unusual Expense (Income)
NOPBT
150,049
133,332
92,971
NOPBT Margin
24.12%
22.06%
18.16%
Operating Taxes
27,314
26,376
9,799
Tax Rate
18.20%
19.78%
10.54%
NOPAT
122,735
106,956
83,172
Net income
165,828
18.95%
139,404
59.02%
87,667
38.47%
Dividends
(42,350)
(56,267)
Dividend yield
0.98%
1.49%
Proceeds from repurchase of equity
957
247,250
BB yield
-0.02%
-6.54%
Debt
Debt current
50
2,462
Long-term debt
16,918
Deferred revenue
Other long-term liabilities
19
19
120
Net debt
(863,832)
(810,092)
(529,656)
Cash flow
Cash from operating activities
171,200
268,338
117,593
CAPEX
(22,441)
(14,442)
(15,446)
Cash from investing activities
(490,246)
10,432
(2,775)
Cash from financing activities
(41,393)
(1,051)
188,691
FCF
93,538
227,075
94,536
Balance
Cash
432,582
801,264
540,177
Long term investments
431,300
8,828
8,859
Excess cash
832,776
779,870
523,437
Stockholders' equity
1,088,788
1,295,657
1,141,718
Invested Capital
528,396
488,637
618,860
ROIC
24.14%
19.31%
13.10%
ROCE
11.02%
10.51%
8.14%
EV
Common stock shares outstanding
89,453
89,415
84,064
Price
48.40
6.65%
45.38
0.98%
44.94
126.63%
Market cap
4,329,525
6.70%
4,057,646
7.41%
3,777,852
136.27%
EV
3,465,693
3,247,554
3,248,196
EBITDA
177,665
162,914
125,872
EV/EBITDA
19.51
19.93
25.81
Interest
68
196
Interest/NOPBT
0.05%
0.21%